19
1
Cat. No. | Product Name | Target | Signaling Pathways |
---|---|---|---|
T8916 |
WEE1-IN-3
JUN76288 |
Wee1 | Cell Cycle/Checkpoint |
WEE1-IN-3 (JUN76288) 是一种有效的 Wee1激酶抑制剂,IC50小于 10 nM。它治疗癌症和其他增殖性疾病。 | |||
T23869 |
WEE1-IN-4
Wee1-Inhibitor-I,Wee1 Inhibitor-I,Wee1 Inhibitor I,Wee1-Inhibitor I |
||
Wee1 Inhibitor I is an ATP-binding site-targeting Wee1 inhibitor. | |||
T9864 |
Debio-0123
WEE1-IN-5 |
Wee1 | Cell Cycle/Checkpoint |
Debio-0123 (WEE1-IN-5) 是一种口服有效且高度特异性的WEE1抑制剂,IC50值在低纳摩尔范围内。Debio-0123 抑制磷酸化 CDC2。Debio-0123 可增强卡铂在体内的抗肿瘤活性,而这两种药物单独使用都没有活性。 | |||
T23881 |
Wee1 Inhibitor II
Wee1-Inhibitor II,Wee1-Inhibitor-II,Wee1 Inhibitor-II |
||
Wee1 Inhibitor II is an ATP-binding site-targeting Wee1 inhibitor. | |||
T6931 |
PD0166285
PD-166285 |
Apoptosis; Wee1; Chk | Apoptosis; Cell Cycle/Checkpoint |
PD0166285是 P-gp 的底物,是一种有效的 Wee1 和 Chk1 抑制剂弱抑制。 | |||
T2077 |
Adavosertib
AZD1775,MK-1775,Adavosertib (MK-1775) |
Wee1 | Cell Cycle/Checkpoint |
Adavosertib (MK-1775) 是一种Wee1抑制剂,IC50值为 5.2 nM。它阻碍了 G2 DNA 损伤检查点。 | |||
T16446 |
PD 407824
PD-407824 |
Wee1; Chk | Cell Cycle/Checkpoint |
PD 407824 是一种化学 BMP 增敏剂,能促进细胞对亚阈值量 BMP4 的敏感性提高。PD 407824 是一种高效的检查点激酶 Chk1 和 WEE1 抑制剂(IC50 分别为 47 和 97 nM)。 | |||
T9643 |
ZN-c3
|
Wee1 | Cell Cycle/Checkpoint |
ZN-c3 是一种有效的选择性 Wee1 抑制剂,具有平衡的效力、ADME 和药代动力学特性。 | |||
T41163 |
ZNL 02-096
Pomalidomide-C3-adavosertib |
Apoptosis; Wee1 | Apoptosis; Cell Cycle/Checkpoint |
ZNL 02-096 (Pomalidomide-C3-adavosertib) 是一种快速和选择性的 Wee1 降解剂 (IC50=3.58 nM)。ZNL 02-096 可在亚摩尔浓度下选择性降解 Wee1,而不损伤 AZD 1775 的二级靶点 PLK1。在体外 MOLT-4 细胞中,ZNL 02-096 可诱导 Wee1 降解、DNA 损伤积累、细胞周期停滞在 G2/M 期和细胞凋亡。ZNL 02-096 在 300 种癌症细胞系中显示出抗增殖作用。 | |||
T70126 | CJM-061 | ||
CJM-061 is a Wee1 inhibitor. | |||
T71067 | MK-1775 hemihydrate | ||
MK-1775 hemihydrate is a WEE1 inhibitor with potential antineoplastic sensitizing activity. | |||
T74371 |
LEB-03-146
|
||
LEB-03-146是一种WEE1DUBTAC(去泛素化酶靶向嵌合体),通过PEG2连接剂把AZD1775 (Adavosertib) 和OTUB1招募者EN523相连。在HEP3B肝癌细胞中,LEB-03-146能显著增强WEE1的稳定性。 | |||
T74275 | LEB-03-144 | ||
LEB-03-144 是一个 WEE1DUBTAC (去泛素化酶靶向嵌合体),通过 C3 烷基连接剂将 AZD1775 (Adavosertib) 与 OTUB1招募者 EN523 连接起来。LEB-03-144 在 HEP3B 肝癌细胞中可显著稳定WEE1。 | |||
T74276 | LEB-03-153 | ||
LEB-03-153 是一个WEE1DUBTAC (去泛素化酶靶向嵌合体),通过无连接剂将 AZD1775 (Adavosertib) 连接到OTUB1的招募者 EN523。 | |||
T74274 | LEB-03-145 | ||
LEB-03-145 是一个WEE1DUBTAC (去泛素化酶靶向嵌合体),通过 C5 烷基连接剂将 AZD1775 (Adavosertib) 与OTUB1招募者 EN523 连接起来。 | |||
T71462 | GUN94110 | ||
GUN94110 is a WEE1 kinase inhibitors useful in treatment of cancer and other proliferative diseases. GUN94110 was reported in WO 2019028008. This product has no formal name at the moment. For the convenience of communication, a temporary code name was therefore proposed according to MedKoo Chemical Nomenclature (see web page: https://www.medkoo.com/page/naming). | |||
T82385 |
FMF-06-098-1
|
PROTACs | PROTAC |
FMF-06-098-1是一种多靶点蛋白降解剂。通过专一性降解作用,FMF-06-098-1针对多种激酶,能够有效降解AAK1, ABL2, AURKA, AURKB, BUB1B, CDC7, CDK1, CDK12, CDK13, CDK2, CDK4, CDK6, CDK7, CDK9, CHEK1, CSNK1D, EPHA1, PER, FGFR1, GAK, IRAK4, ITK, LIMK2, MAP4K2, MAP4K3, MAPK6, MAPK7, MARK4, MELK, PKN3, PLK4, PRKAA1, PTK2, PTK6, RPS6KA4, S1K2, STK35, TNK2, UHMK1, ULK1及WEE1等关键蛋白。 | |||
T74644 |
DB0614
|
||
DB1113 (Example 24) 是一种靶向蛋白激酶降解的双功能化合物。DB1113 可降解ABL1,ABL2,BLK,CDK11B,CDK4,CSK,EPHA3,FER,GAK,LIMK1,MAP3K20,MAP4K1,MAP4K2,MAP4K3,MAP4K5,MAPK14,MAPK7,MAPK8,MAPK9,MAPKAPK2,MAPKAPK3,NLK,PDIK1L,PTK2B,RIPK1,RPS6KA1,RPS6KA3,SIK2,SIK3,STK35,TNK2 和ULK1。DB1113 可用于研究异常激酶活性介导的疾病或紊乱。 | |||
T6931L |
PD0166285 dihydrochloride
PD-166285 |
||
PD-166285 is an effective and broadly active inhibitor of protein tyrosine kinase. |
Cat. No. | Product Name | Target | Signaling Pathways |
---|---|---|---|
T3S0737 |
Flavokawain A
2'-羟基-4,4',6'-三甲氧基查耳酮,Flavokavain A |
Apoptosis; p38 MAPK | Apoptosis; MAPK |
Flavokawain A (Flavokavain A) 是 kava 提取物中的查耳酮,是一种抗癌试剂,具有抗肿瘤活性。它通过 Bax 蛋白依赖和线粒体依赖的凋亡途径诱导细胞凋亡,有潜力用于膀胱癌的相关研究。 |